Q-omics provides the consensus-scored LRRC8E profile across patient tissues and cancer cell-line models. LRRC8E expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LRRC8E is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, LRRC8E RNA expression shows 17,409 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, COAD, and THYM as cancer lineages where LRRC8E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC8E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC8E survival associations across molecular data types. LRRC8E RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC8E RNA expression–survival associations across cancer types. High LRRC8E expression shows unfavorable associations in MESO, PAAD and LGG, but favorable associations in ACC, HNSC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LRRC8E RNA expression.
This table summarizes LRRC8E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRC8E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC8E shows higher tumor expression in COAD, HNSC, BLCA, UCEC, BRCA and KIRP. The COAD box plot shows higher LRRC8E RNA expression in tumor versus normal tissue (log2 FC = +1.119, t-test p < 0.001).
This table shows molecular features associated with LRRC8E in patient tissues and cancer cell lines. In patient samples, LRRC8E shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC8E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
